XML 88 R20.htm IDEA: XBRL DOCUMENT
v3.26.1

INVESTMENTS MEASURED AT FAIR VALUE | 12 Months Ended
--- | ---
Dec. 31, 2025
Investments, All Other Investments [Abstract] |
INVESTMENTS MEASURED AT FAIR VALUE | 11. INVESTMENTS MEASURED AT FAIR VALUE Financial assets measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheets as of December 31, 2025 and 2024: SCHEDULE OF FINANCIAL ASSETS MEASURED AT FAIR VALUE ON A RECURRING BASIS
|  | Fair Value Measurement Using |  |  | Amount at |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Fair Value |
December 31, 2025 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment Securities at Fair Value - Related Parties |  | $ | 3,683,925 |  |  | $ | 48,115 |  |  | $ | - |  |  | $ | 3,732,040 |
Investment Securities at Fair Value - Third Parties |  |  | 14,264,655 |  |  |  | 418,605 |  |  |  | - |  |  |  | 14,683,260 |
Warrants - HIPH |  |  | - |  |  |  | - |  |  |  | 973 |  |  |  | 973 |
Warrants - VEII |  |  | - |  |  |  | 18,301 |  |  |  | - |  |  |  | 18,301 |
Warrants - SHRG |  |  | - |  |  |  | 87 |  |  |  | - |  |  |  | 87 |
Convertible Note Receivable - VEII |  |  | - |  |  |  | 517,275 |  |  |  | - |  |  |  | 517,275 |
Convertible Note Receivable - SHRG |  |  | - |  |  |  | 1,736,829 |  |  |  | - |  |  |  | 1,736,829 |
Total Investment in Securities at Fair Value |  | $ | 17,948,580 |  |  | $ | 2,739,211 |  |  | $ | 973 |  |  | $ | 20,688,764 |
|  | Fair Value Measurement Using |  |  | Amount at |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Fair Value |
December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment Securities at Fair Value - Related Parties |  | $ | 3,565,089 |  |  | $ | 7,463,324 |  |  | $ | - |  |  | $ | 11,028,413 |
Investment Securities at Fair Value - Third Parties |  |  | 2,612,293 |  |  |  | 2,061,230 |  |  |  | - |  |  |  | 4,673,523 |
Warrants - HIPH |  |  | - |  |  |  | - |  |  |  | 973 |  |  |  | 973 |
Warrants - VEII |  |  | - |  |  |  | 1,299,973 |  |  |  | - |  |  |  | 1,299,973 |
Warrants - SHRG |  |  | - |  |  |  | 13,272 |  |  |  | - |  |  |  | 13,272 |
Convertible Note Receivable - VEII |  |  | - |  |  |  | 569,630 |  |  |  | - |  |  |  | 569,630 |
Convertible Note Receivable - SHRG |  |  | - |  |  |  | 1,212,746 |  |  |  | - |  |  |  | 1,212,746 |
Total Investment in Securities at Fair Value |  | $ | 6,177,382 |  |  | $ | 12,620,175 |  |  | $ | 973 |  |  | $ | 18,798,530 |
Realized loss on investment securities for the year ended December 31, 2025 was $3,208,972 and realized gain on investment securities for the year ended December 31, 2024 was $461,247. Unrealized loss on securities investment was $2,451,237 and $942,213 in the years ended December 31, 2025 and 2024, respectively. These gains and losses were recorded directly to net loss. The following chart shows details of the fair value of equity security investment at December 31, 2025 and December 31, 2024, respectively. SCHEDULE OF FAIR VALUE OF EQUITY SECURITY INVESTMENT
|  | Share price |  |  |  |  |  | Market Value |  |  |
|  | 12/31/2025 |  |  | Shares |  |  | 12/31/2025 |  |  | Valuation
DSS (Related Party) |  | $ | 0.930 |  |  |  | 3,961,210 |  |  | $ | 3,683,925 |  |  | Investment in Securities at Fair Value
Investment Securities at Fair Value - Third Parties |  |  |  |  |  |  |  |  |  | $ | 14,264,655 |  |  | Investment in Securities at Fair Value
|  |  | Total Level 1 Equity Securities |  |  | $ | 17,948,580 |  |  |
Holista |  | $ | 0.057 |  |  |  | 1,000 |  |  | $ | 57 |  |  | Investment in Securities at Fair Value
HIPH World (Related Party) |  | $ | 0.000 |  |  |  | 354,039,000 |  |  | $ | 35,404 |  |  | Investment in Securities at Fair Value
AMBS |  | $ | 0.000 |  |  |  | 20,000,000 |  |  | $ | 0 |  |  | Investment in Securities at Fair Value
Value Exchange (Related Party) |  | $ | 0.001 |  |  |  | 21,179,275 |  |  | $ | 10,590 |  |  | Investment in Securities at Fair Value
Sharing Services (Related Party) |  | $ | 0.023 |  |  |  | 89,732 |  |  | $ | 2,064 |  |  | Investment in Securities at Fair Value
Investment Securities at Fair Value - Third Parties |  |  |  |  |  |  |  |  |  | $ | 418,605 |  |  | Investment in Securities at Fair Value
|  |  | Total Level 2 Equity Securities |  |  | $ | 466,720 |  |  |
Nervotec |  |  | N/A |  |  |  | 1,666 |  |  | $ | 0 |  |  | Investment in Securities at Cost
K Beauty |  |  | N/A |  |  |  | 3,600 |  |  | $ | 16,696 |  |  | Investment in Securities at Cost
Ideal Food and Beverages |  |  | N/A |  |  |  | 19,000 |  |  | $ | 0 |  |  | Investment in Securities at Cost
HapiTravel Holding |  |  | N/A |  |  |  | 19,000 |  |  | $ | 148 |  |  | Investment in Securities at Cost
AES Group Co. Ltd. |  |  | N/A |  |  |  | 398 |  |  | $ | 1,382 |  |  | Investment in Securities at Cost
|  |  | Total Equity Securities |  |  | $ | 18,433,526 |  |  |
|  | Share price |  |  |  |  |  | Market Value |  |  |
|  | 12/31/2024 |  |  | Shares |  |  | 12/31/2024 |  |  | Valuation
DSS (Related Party) |  | $ | 0.900 |  |  |  | 3,961,210 |  |  | $ | 3,565,089 |  |  | Investment in Securities at Fair Value
Trading Stock |  |  |  |  |  |  |  |  |  | $ | 2,612,293 |  |  | Investment in Securities at Fair Value
|  |  | Total Level 1 Equity Securities |  |  | $ | 6,177,382 |  |  |
Holista |  | $ | 0.008 |  |  |  | 1,000 |  |  | $ | 8 |  |  | Investment in Securities at Fair Value
New Electric CV (Related Party) |  | $ | 0.000 |  |  |  | 354,039,000 |  |  | $ | 0 |  |  | Investment in Securities at Fair Value
AMBS |  | $ | 0.000 |  |  |  | 20,000,000 |  |  | $ | 0 |  |  | Investment in Securities at Fair Value
Value Exchange (related Party) |  | $ | 0.035 |  |  |  | 21,179,275 |  |  | $ | 749,746 |  |  | Investment in Securities at Fair Value
Sharing Services (Related Party) |  | $ | 1.000 |  |  |  | 89,732 |  |  | $ | 89,732 |  |  | Investment in Securities at Fair Value
Impact BioMedical (Related Party) |  | $ | 1.450 |  |  |  | 4,568,165 |  |  | $ | 6,623,838 |  |  | Investment in Securities at Fair Value
Trading Stock |  |  |  |  |  |  |  |  |  | $ | 2,061,230 |  |  | Investment in Securities at Fair Value
|  |  | Total Level 2 Equity Securities |  |  | $ | 9,524,554 |  |  |
Nervotec |  |  | N/A |  |  |  | 1,666 |  |  | $ | 589 |  |  | Investment in Securities at Cost
K Beauty |  |  | N/A |  |  |  | 3,600 |  |  | $ | 16,733 |  |  | Investment in Securities at Cost
Ideal Food and Beverages |  |  | N/A |  |  |  | 19,000 |  |  | $ | 0 |  |  | Investment in Securities at Cost
HapiTravel Holding |  |  | N/A |  |  |  | 19,000 |  |  | $ | 140 |  |  | Investment in Securities at Cost
|  |  | Total Equity Securities |  |  | $ | 15,719,398 |  |  |
Changes in the observable input values would likely cause material changes in the fair value of the Company’s Level 3 financial instruments. A significant increase (decrease) in this likelihood would result in a higher (lower) fair value measurement. The table below provides a summary of the changes in fair value which are recorded through other income (loss), including net transfers in and/or out of all financial assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the years ended December 31, 2025 and 2024: SCHEDULE OF CHANGE IN FAIR VALUE
|  | Total |
Balance at January 1, 2024 |  | $ | 77,737 |
Impairment |  |  | (77,307 | )
Net loss |  |  | 543 |
Balance at December 31, 2024 |  | $ | 973 |
Net gain |  |  | - |
Net gain |  |  | - |
Balance at December 31, 2025 |  | $ | 973 |
Vector Com Convertible Bond On February 26, 2021, the Company invested approximately $88,599 in the convertible note of Vector Com Co., Ltd (“Vector Com”), a private company in South Korea. The interest rate is 2% per annum. The conversion price is approximately $21.26 per common share of Vector Com. As of December 31, 2023, the Management estimated the fair value of the note to be $77,307. The Company wrote off this loan at March 31, 2024. Warrants HIPH On July 17, 2020, the Company purchased 122,039,000 shares, approximately 0.5% ownership, and 1,220,390,000 warrants with an exercise price of $0.0001 per share, from HIPH, for an aggregated purchase price of $122,039. During 2021, the Company exercised 232,000,000 of the warrants to purchase 232,000,000 shares of HIPH for the total consideration of $232,000, leaving the balance of outstanding warrants of 988,390,000 at December 31, 2021. The Company did not exercise any warrants during years ended December 31, 2025 and 2024. We value HIPH warrants under level 3 category through a Black Scholes option pricing model and the fair value of the warrants from HIPH was $973 as of December 31, 2025 and 2024. The fair value of the HIPH warrants under level 3 category as of December 31, 2025 and 2024 was calculated using a Black-Scholes valuation model valued with the following weighted average assumptions: SCHEDULE OF SIGNIFICANT INPUTS AND ASSUMPTIONS
|  | December 31, 2025 |  |  | December 31, 2024 |
Stock Price |  | $ | 0.0001 |  |  | $ | 0.0001 |
Exercise Price |  | $ | 0.001 |  |  | $ | 0.001 |
Risk-free Interest Rate |  |  | 4.62 | % |  |  | 4.62 | %
Annualized volatility |  |  | 869.4 | % |  |  | 869.4 | %
Dividend Yield |  |  | 0.00 |  |  |  | 0.00 |
Year to Maturity |  |  | 4.56 |  |  |  | 5.56 |
VEII On September 6, 2023, the Company received warrants to purchase shares of VEII, a related party listed company. For further details on this transaction, refer to Note 7 - Related Party Transactions, Note Receivable from a Related Party. As of December 31, 2025 and 2024, the fair value of the warrants was $18,301 and $1,299,973, respectively. The Company did not exercise any warrants during the years ended December 31, 2025 and 2024. The fair value of the VEII warrants under level 3 category as of December 31, 2025 and 2024 was calculated using a Black-Scholes valuation model valued with the following weighted average assumptions: SCHEDULE OF SIGNIFICANT INPUTS AND ASSUMPTIONS
|  | December 31, 2025 |  |  | December 31, 2024 |
Stock Price |  | $ | 0.0005 |  |  | $ | 0.0354 |
Exercise Price |  | $ | 0.1770 |  |  | $ | 0.1770 |
Risk-free Interest Rate |  |  | 6.75 | % |  |  | 7.50 | %
Annualized volatility |  |  | 446.80 | % |  |  | 458.92 | %
Dividend Yield |  |  | 0.00 |  |  |  | 0.00 |
Year to Maturity |  |  | 2.68 |  |  |  | 3.68 |
SHRG On March 20, 2024, HWH International Inc., entered into a securities purchase agreement with SHRG, pursuant to which HWH purchased from SHRG a (i) Convertible Promissory Note in the amount of $250,000, convertible into 148,810 shares of SHRG’s common stock at the option of HWH, and (ii) certain warrants exercisable into 148,810 shares of SHRG’s common stock at an exercise price of $1.68 per share, the exercise period of the warrant being five (5) years from the date of the securities purchase agreement, for an aggregate purchase price of $250,000. At the time of this filing, HWH has not converted any of the debt contemplated by the Convertible Note nor exercised any of the warrants. As of December 31, 2025 and 2024, the fair value of the warrants was $12 and $13,272, respectively. The fair value of the SHRG warrants under level 2 category as of December 31, 2025, was calculated using binomial option pricing model valued with the following weighted average assumptions: SCHEDULE OF SIGNIFICANT INPUTS AND ASSUMPTIONS
|  | December 31, 2025 |  |  | December 31, 2024 |
Stock Price |  | $ | 0.0230 |  |  | $ | 1.0000 |
Exercise Price |  | $ | 1.6800 |  |  | $ | 1.6800 |
Risk-free Interest Rate |  |  | 3.56 | % |  |  | 4.34 | %
Annualized volatility |  |  | 390.99 | % |  |  | 204.14 | %
Dividend Yield |  |  | 0.00 |  |  |  | 0.00 |
Year to Maturity |  |  | 3.21 |  |  |  | 4.21 |
On March 31, 2025, HWH entered into a securities purchase agreement with the SHRG, pursuant to which SHRG issued a convertible promissory note to HWH in the amount of $150,000. This SHRG Convertible Note is convertible into SHRG’s common stock at $0.80 per share at HWH’s option until maturity three (3) years from the date of the securities purchase agreement. In addition, SHRG granted HWH warrants exercisable into 937,500 shares of SHRG’s common stock. The warrants may be exercised for three (3) years from the date of the securities purchase agreement at an exercise price of $0.85 per share. At the time of this filing, HWH has not converted any of the debt contemplated by the Convertible Note nor exercised any of the warrants. As of December 31, 2025, the fair value of the warrants was $75. The fair value of the 937,500 SHRG warrants under level 2 category as of December 31, 2025, was calculated using binomial option pricing model valued with the following weighted average assumptions: SCHEDULE OF SIGNIFICANT INPUTS AND ASSUMPTIONS
|  | December 31, 2025 |
Stock Price |  | $ | 0.0230 |
Exercise Price |  | $ | 0.8500 |
Risk-free Interest Rate |  |  | 3.49 | %
Annualized volatility |  |  | 390.99 | %
Dividend Yield |  |  | 0.00 |
Year to Maturity |  |  | 2.25 |
Convertible Note Receivables The Company has elected to recognize the convertible note receivables at fair value and therefore there was no further evaluation of embedded features for bifurcation. The Company engaged third party valuation firm to perform the valuation of convertible notes. The fair value of the convertible notes is calculated using the binomial tree model based on probability of remaining as straight debt using discounted cash flow. During the year ended December 31, 2025, the Company reclassified “Investment in securities at fair value – related party,” “Investment in security at cost,” “Investment in equity method securities” and some of “Convertible Note Receivables at Fair Value – Related Party” from current assets to noncurrent assets in the consolidated balance sheet based on management’s assessment of the expected holding period. This change in classification had no impact on the Company’s consolidated statements of operations, cash flows, or shareholders’ equity. The following table presents summarized unaudited financial information for our investments that we elected the fair value option that would otherwise be accounted for under the equity method of accounting. SCHEDULE OF SUMMARIZED UNAUDITED FINANCIAL INFORMATION OF EQUITY METHOD INVESTMENTS
|  | Summarized Financial Information |
|  | Assets |  |  | Liabilities |  |  | Net Loss |
December 31, 2025 |  |  |  |  |  |  |  |  |  |  |  |
HIPH |  | $ | 12,627,000 |  |  | $ | 2,218,000 |  |  | $ | (361,000 | )
DSS* |  | $ | 92,123,000 |  |  | $ | 66,015,000 |  |  | $ | (13,449,000 | )
VEII** |  | $ | 6,844,729 |  |  | $ | 10,744,581 |  |  | $ | (640,853 | )
SHRG*** |  | $ | 6,257,230 |  |  | $ | 10,470,791 |  |  | $ | (2,869,424 | )
December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |
HIPH |  | $ | 12,684,000 |  |  | $ | 2,254,000 |  |  | $ | (283,000 | )
DSS |  | $ | 106,453,000 |  |  | $ | 73,737,000 |  |  | $ | (53,706,000 | )
VEII** |  | $ | 6,844,729 |  |  | $ | 10,744,581 |  |  | $ | (640,853 | )
SHRG*** |  | $ | 6,257,230 |  |  | $ | 10,470,791 |  |  | $ | (2,869,424 | )
* | Data derived from Financial Statement as of September 30, 2025, which was the latest available date source we could reach. 12-month Net Loss was estimated by adding one-third of 9-month Net Loss.
** | Data derived from Financial Statement as of September 30, 2024, which was the latest available date source we could reach. 12-month Net Loss was estimated by adding one-third of 9-month Net Loss.
*** | Data derived from Financial Statement as of September 30, 2024, which was the latest available date source we could reach. 12-month Net Loss was estimated by doubling the 6-month Net Loss.

X
- Definition The entire disclosure for investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 321 -Publisher FASB -URI https://asc.fasb.org/321/tableOfContent Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 325 -Publisher FASB -URI https://asc.fasb.org/325/tableOfContent + Details
Name: | us-gaap_InvestmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration